First AD

Second AD

Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study

Video content above is prompted by the following:

How might the approval of tafasitamab + R

in the 2L setting alter or impact your decision-making process in the 1L or 3L+ treatment settings?

Feel free to share your thoughts on any differences and/or similarities in your impressions of the inMIND study and how tafasitamab + R

 might impact your clinical practice. What key highlights or data points stand out to you?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights

Peer Exchange

Panelists discuss how the approval of tafasitamab + lenalidomide and rituximab (R2) in the second-line (2L) setting might influence decision-making in the first-line (1L) or third line–plus (3L+) treatment settings and share their thoughts on the inMIND study, highlighting key data points and the impact of tafasitamab + R2 on clinical practice.